Ro as Preferred Distribution Channel

Ro is moving from being a telehealth storefront to being part of the launch machinery for obesity drugs. The key asset is not just patient demand, it is the combination of prescribing workflow, pharmacy routing, payer approval data, and follow up care. That gives drugmakers a live view into why patients get blocked, what support they need, and which commercial path can turn a prescription into a filled order at scale.

• The Amgen collaboration is about observational research on real patients trying to get GLP-1 treatment, including coverage rules and prior authorization friction. That makes Ro useful before launch, because it helps a manufacturer design access strategy around the real bottlenecks that stop adoption.
  1 ro 2 sacra
• Ro already sits inside manufacturer distribution for current GLP-1s. Lilly launched LillyDirect in January 2024, and Ro later became a front end that can route patients into manufacturer backed supply while keeping the care experience inside Ro. That is the template for future preferred channel status.
  3 lilly 4 sacra
• This is a different position from companies that mainly sell coaching or benefits management. Ro controls patient acquisition, telehealth intake, prescribing, pharmacy coordination, and refill follow up in one flow, which makes it more valuable to a drugmaker trying to launch a new therapy fast.
  2 sacra 4 sacra 5 sacra 6 sacra

The next step is for obesity drug launches to look more like software rollouts, with Ro handling demand capture, eligibility checks, payer navigation, and first fill conversion from day one. If that model sticks, the winners in telehealth will be the companies manufacturers trust to turn clinical innovation into actual patient starts.